[A case of CA19-9 producing gastric cancer treated by low-dose administration of TS-1 for adjuvant chemotherapy].
A 72-year-old woman underwent total gastrectomy for CA19-9 producing gastric cancer. TS-1 was administered for recurrent gastric cancer because the duodenal stump was histologically positive and the serum CA19-9 level elevated after temporary regression. The dose was reduced from 80 mg/body/day to 50 mg/body/day because of grade 3 neutropenia. One course consisted of consecutive administration for 28 days followed by 14 days' rest. Upon the completion of the second course, the serum CA19-9 level became within normal limits, and no recurrence nor remarkable adverse reaction has been recognized for 6 courses. Adjuvant use of TS-1 for gastric cancer is ongoing as clinical trials, however, the incidence of adverse reaction does not seem to be negligible with administration of the recommended dose. Low-dose administration of TS-1 is thought to be one effective method of postoperative adjuvant chemotherapy for gastric cancer.
Takashima
Ikuhiro
I
Dept of Surgery, Hiroshima Mitsubishi Hospital.
Seto
Yoshihiro
Y
Nagamine
Ichiro
I
Kegoya
Yasuhide
Y
Kodoi
Atsunori
A
Nakayama
Hirofumi
H
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D018395:CA-19-9 Antigen / Q000096:biosynthesis* / Q000097:blood; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D005743:Gastrectomy; D006801:Humans; D010094:Oxonic Acid / Q000008:administration & dosage*; D011725:Pyridines / Q000008:administration & dosage*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D005641:Tegafur / Q000008:administration & dosage*
D000964:Antimetabolites, Antineoplastic; D018395:CA-19-9 Antigen; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid